AUCTORES
Globalize your Research

Journal of General Medicine and Clinical Practice
Emmanuel Ifeanyi Obeagu*

Open Access

Review Article

Redox Imbalance and Immune Dysregulation in Sickle Cell Anemia: A Review

Emmanuel Ifeanyi Obeagu

Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science.

***Corresponding Author:** Adrian Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science.

Received date: September 02, 2024; Accepted date: September 16, 2024; Published date: September 23, 2024

Citation: Emmanuel I. Obeagu, (2024), Redox Imbalance and Immune Dysregulation in Sickle Cell Anemia: A Review, *J. General Medicine and Clinical Practice*, 7(16); **DOI:10.31579/2639-4162/221**

Abstract

Disturbance caused by noise causes malfunctioning, reduction of efficiency and negative impact on personal and social life. The purpose of this study is to measure the amount of sound disturbance caused by vehicles and the amount of disturbance based on the standard (ISO15666-2017) in the residents near the Navvab highway. The relationship between the variables was done using non-parametric tests and analysis of variance, and the data was analyzed with spss21. The equivalent sound level was 61 dB during the day and 53 dB at night, which is more than the permissible limit provided by the country (45-50). Also, there is a significant relationship between noise level and nuisance score.

Kew Words: noise annoyance; noise nuisance; vehicle noise; ISO15666

Introduction

Sickle Cell Anemia (SCA) is a hereditary hemoglobinopathy characterized by the production of abnormal hemoglobin S (HbS) due to a point mutation in the β-globin gene. This genetic alteration causes red blood cells (RBCs) to assume a rigid, sickle-like shape under low oxygen conditions, leading to a range of pathological consequences, including chronic hemolysis, vaso-occlusive crises, and significant oxidative stress. The sickling process disrupts normal RBC function, and the resulting damage is further compounded by the ongoing release of free hemoglobin and heme, which contribute to redox imbalance and systemic inflammation. Understanding the interplay between redox imbalance and immune dysregulation is crucial for unraveling the complexities of SCA and developing effective therapeutic strategies. [1-5] The concept of redox imbalance in SCA revolves around the increased generation of reactive oxygen species (ROS) due to hemolysis and sickling of RBCs. ROS are highly reactive molecules that can cause oxidative damage to cellular components, including lipids, proteins, and DNA. In SCA, the breakdown of sickled RBCs releases free hemoglobin and heme into the bloodstream, which further exacerbates oxidative stress. This imbalance not only damages RBCs but also affects other cells and tissues throughout the body, contributing to chronic inflammation and a cascade of pathological events. The elevated oxidative stress observed in SCA underscores the need to explore how this redox imbalance influences immune system function and contributes to disease complications. [6-10] Immune dysregulation in SCA is closely linked to the increased oxidative stress and systemic inflammation caused by redox imbalance. The immune system is highly sensitive to changes in the oxidative environment, and oxidative stress can impair the function of various immune cells, including neutrophils, macrophages, and lymphocytes. In SCA, the chronic inflammation driven by oxidative stress disrupts normal immune responses, leading to an increased risk of infections and exacerbation of disease symptoms. This immune dysfunction is characterized by altered cytokine profiles, impaired phagocytic activity, and skewed lymphocyte responses, all of which contribute to the overall disease burden in SCA patients. [11-13] The interaction between oxidative stress and immune dysregulation in SCA has significant clinical implications. Patients with SCA often experience recurrent infections, delayed wound healing, and more severe vaso-occlusive crises due to the combined effects of redox imbalance and immune dysfunction. [14-15]

Redox Imbalance in Sickle Cell Anemia

Redox imbalance, characterized by an excess of reactive oxygen species (ROS) and a deficit in antioxidant defenses, is a hallmark of Sickle Cell Anemia (SCA). This imbalance originates from the sickling of red blood cells (RBCs) and the subsequent hemolysis, leading to significant oxidative stress throughout the body. Understanding the mechanisms of redox imbalance in SCA is crucial for elucidating the broader pathophysiology of the disease and identifying potential therapeutic targets. [16-18] In SCA, the sickling of RBCs under low oxygen conditions disrupts normal cell function and triggers a cascade of oxidative reactions. The abnormal hemoglobin S (HbS) within these sickled cells undergoes continuous oxidation, leading to the release of free hemoglobin and heme into the bloodstream. These released components are highly pro-oxidative and contribute to elevated ROS levels. ROS, such as superoxide anions, hydrogen peroxide, and hydroxyl radicals, are highly reactive molecules that can damage cellular macromolecules, including lipids, proteins, and nucleic acids. This oxidative damage exacerbates the pathological processes in SCA, leading to further cell dysfunction and tissue injury. [19-23] The release of free hemoglobin and heme from lysed RBCs not only increases ROS levels but also depletes key antioxidant defenses. Normally, the body relies on antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase to

neutralize ROS and protect cells from oxidative damage. However, in SCA, the oxidative load often overwhelms these antioxidant systems, leading to a state of redox imbalance. The depletion of antioxidant defenses further compounds oxidative stress and contributes to the progressive damage observed in various tissues, including the endothelium, liver, and kidneys. [24-27]

The consequences of redox imbalance in SCA extend beyond direct cellular damage. Oxidative stress can induce inflammatory responses by activating various signaling pathways, including nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs). These pathways lead to the production and release of pro-inflammatory cytokines and chemokines, which further drive inflammation and contribute to the pathogenesis of vaso-occlusive crises. The chronic inflammation resulting from oxidative stress can exacerbate disease symptoms, including pain episodes and organ damage. [28-30] In addition to inflammatory responses, redox imbalance in SCA affects endothelial function. Endothelial cells lining blood vessels are particularly vulnerable to oxidative damage, which can disrupt normal vascular function and contribute to the development of vaso-occlusive crises. Oxidative stress impairs endothelial nitric oxide production, leading to endothelial dysfunction and promoting vasoconstriction and platelet aggregation. These effects further exacerbate the risk of vaso-occlusive events and contribute to the clinical manifestations of SCA. [31-33]

Immune Dysregulation in Sickle Cell Anemia

Immune dysregulation in Sickle Cell Anemia (SCA) is a critical aspect of the disease's pathophysiology, intricately linked to the oxidative stress and inflammation that characterize this condition. The chronic oxidative stress induced by sickling and hemolysis significantly affects the function and composition of the immune system, leading to a range of immune dysfunctions and increased susceptibility to infections. [34-36] In SCA, the continuous oxidative stress resulting from the breakdown of sickled red blood cells (RBCs) and the release of free hemoglobin and heme disrupts normal immune cell function. Reactive oxygen species (ROS) and inflammatory cytokines generated during this oxidative process can impair the activity of various immune cells, including neutrophils, macrophages, and lymphocytes. This impairment manifests as reduced phagocytic activity, altered cytokine production, and skewed immune responses, all of which contribute to the overall immune dysregulation observed in SCA patients. [37-39] Neutrophils, a key component of the innate immune system, are particularly affected by oxidative stress in SCA. Elevated ROS levels can impair neutrophil function by reducing their ability to effectively engulf and kill pathogens. Additionally, the activation of neutrophils in response to oxidative stress can lead to the excessive release of inflammatory mediators and tissue damage, exacerbating the inflammatory environment in SCA. The dysfunctional neutrophil response contributes to the increased incidence of infections and complications seen in SCA patients. [40-42]

Macrophages, another crucial component of the innate immune system, also experience dysregulation in SCA. Chronic oxidative stress can alter macrophage polarization, shifting their phenotype towards a pro-inflammatory M1 state. This polarization contributes to the sustained inflammation and tissue damage characteristic of SCA. Moreover, the impaired phagocytic function of macrophages further exacerbates the risk of infections and delays wound healing.[43-44] Lymphocytes, including T cells and B cells, are not spared from the effects of oxidative stress in SCA. Altered lymphocyte function, such as impaired T cell activation and reduced antibody production by B cells, compromises the adaptive immune response. This dysregulation contributes to the increased susceptibility to infections and may influence the progression of disease complications. Additionally, the chronic inflammatory environment can further disrupt lymphocyte homeostasis, leading to persistent immune dysfunction. [45-45] The interplay between oxidative stress and immune dysregulation in SCA has significant clinical implications. Patients with SCA are at increased risk of severe infections, delayed wound healing, and more frequent vaso-occlusive crises due to the combined effects of immune dysfunction and chronic inflammation. Addressing these immune dysregulations through targeted therapies could improve patient outcomes and reduce the burden of disease-related complications. [46-48]

Mechanisms Linking Redox Imbalance and Immune Dysregulation

In Sickle Cell Anemia (SCA), redox imbalance and immune dysregulation are closely intertwined, with oxidative stress significantly influencing immune system function. The mechanisms linking these two aspects are complex and involve multiple pathways through which oxidative stress impacts immune cell activity and overall immune responses.[49] Oxidative stress in SCA arises from the sickling of red blood cells (RBCs) and the subsequent release of free hemoglobin and heme into the bloodstream. These components contribute to the generation of reactive oxygen species (ROS), which can directly affect the function of immune cells. For example, ROS can impair the function of neutrophils, macrophages, and lymphocytes by altering their signaling pathways, reducing their ability to respond to infections, and decreasing their phagocytic activity. Oxidative damage to these cells can lead to a decreased ability to clear pathogens and an increased susceptibility to infections.[50] Redox imbalance in SCA triggers the activation of various inflammatory pathways, such as nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs). These pathways are critical in regulating the production of pro-inflammatory cytokines and chemokines. In SCA, the elevated levels of ROS activate NF-κB and MAPKs, leading to an overproduction of inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). This chronic inflammation not only contributes to the clinical manifestations of SCA, such as vaso-occlusive crises, but also further disrupts immune cell function.[51]

Endothelial cells are highly sensitive to oxidative stress. In SCA, oxidative damage to endothelial cells disrupts their normal function, leading to endothelial dysfunction. This dysfunction is characterized by reduced production of nitric oxide, a key regulator of vascular tone and immune cell adhesion. The impaired endothelial function results in increased adhesion of immune cells to the vessel walls, contributing to inflammation and the development of vaso-occlusive crises. This chronic endothelial activation exacerbates immune dysregulation by creating a pro-inflammatory environment.[52] The imbalance between ROS production and antioxidant defenses plays a significant role in immune dysregulation in SCA. In healthy individuals, antioxidants such as superoxide dismutase (SOD), catalase, and glutathione peroxidase neutralize ROS and protect cells from oxidative damage. However, in SCA, the high levels of ROS often overwhelm these antioxidant systems, leading to oxidative damage and reduced immune cell function. The depletion of antioxidants further exacerbates oxidative stress and contributes to immune dysfunction.[53] Oxidative stress can alter immune cell signaling pathways, affecting their activation and response. For instance, ROS can modify key signaling molecules and transcription factors involved in immune responses. This modification can lead to altered cytokine production, impaired cell signaling, and reduced effectiveness of immune responses. The dysregulation of these pathways contributes to the persistent inflammation and immune dysfunction observed in SCA.[54] Chronic oxidative stress and inflammation in SCA may also affect immune tolerance mechanisms, potentially leading to autoimmunity. The persistent oxidative damage can alter self-antigens, leading to the generation of autoantibodies and autoimmune responses. This dysregulation of immune tolerance further complicates the clinical management of SCA and contributes to the overall disease burden.[55]

Impact on Clinical Manifestations

The interplay between redox imbalance and immune dysregulation in Sickle Cell Anemia (SCA) significantly affects the clinical manifestations and overall disease burden. One of the most prominent clinical manifestations of SCA is the occurrence of vaso-occlusive crises, which result from the blockage of blood flow in small vessels due to the sickling of red blood cells (RBCs). Redox imbalance exacerbates these crises by promoting endothelial dysfunction and inflammation. Oxidative stress damages endothelial cells, reducing their ability to produce nitric oxide, a key vasodilator. The subsequent increase in vascular inflammation and endothelial activation enhances the adhesion of sickled cells to the vessel walls, aggravating the

blockage and leading to severe pain, tissue ischemia, and organ damage.[56] Immune dysregulation in SCA results in impaired immune cell function, including reduced phagocytic activity and altered cytokine production. This dysfunction leads to an increased susceptibility to infections, which can complicate the management of SCA. Patients with SCA often experience recurrent infections, particularly from encapsulated bacteria such as Streptococcus pneumoniae. The chronic oxidative stress further impairs immune responses, making it challenging for patients to mount effective defenses against pathogens and increasing the risk of severe infections.[57]

Chronic oxidative stress and inflammation in SCA can also impair wound healing. The oxidative damage to cells and tissues affects the normal repair processes, leading to delayed healing of wounds and ulcers. Additionally, the compromised immune response and persistent inflammation further hinder the healing process. This impact on wound healing contributes to the overall morbidity and reduced quality of life in SCA patients. The chronic oxidative stress and inflammation associated with SCA can lead to significant organ damage. For example, oxidative damage to the kidneys can result in renal dysfunction, while oxidative stress and inflammation in the liver can contribute to hepatopathy. Endothelial dysfunction and increased inflammation can also lead to cardiovascular complications. The cumulative effect of these damages exacerbates the disease burden and can lead to severe long-term health consequences.[55] Hemolysis is a key feature of SCA, and the associated redox imbalance further exacerbates anemia. The breakdown of sickled RBCs releases free hemoglobin and heme into the bloodstream, leading to increased oxidative stress and the depletion of key antioxidants. The resulting oxidative damage to RBC membranes accelerates hemolysis, contributing to the chronic anemia observed in SCA patients. This anemia can lead to fatigue, weakness, and other systemic symptoms, further impacting the quality of life. Emerging research suggests that redox imbalance and chronic inflammation may also affect cognitive function in SCA patients. The oxidative stress and inflammation associated with the disease can impact cerebral blood flow and neuronal function, potentially leading to cognitive deficits and developmental delays, particularly in pediatric patients. Addressing these aspects of the disease may be crucial for improving overall cognitive health and development in affected individuals.[56]

Conclusion

The interplay between redox imbalance and immune dysregulation plays a crucial role in the pathophysiology of Sickle Cell Anemia (SCA). The chronic oxidative stress resulting from the sickling of red blood cells and subsequent hemolysis leads to a cascade of detrimental effects on immune system function and overall clinical outcomes. Elevated levels of reactive oxygen species (ROS) and the resulting oxidative damage significantly impair immune cell function, contributing to chronic inflammation and increased susceptibility to infections. The impact of redox imbalance on clinical manifestations in SCA is profound. The oxidative stress and inflammatory responses driven by ROS lead to a range of complications, including vaso-occlusive crises, delayed wound healing, and frequent infections. The disruption of normal immune function and endothelial cell activity exacerbates these clinical issues, further complicating the management of the disease.

References

1. Alenzi FQ, AlShaya DS. (2019). Biochemical and molecular analysis of the beta-globin gene on Saudi sickle cell anemia. Saudi Journal of Biological Sciences;26(7):1377-1384.
2. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. (2015). Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences;3(6B):224422-224452.
3. Obeagu EI. (2020). Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences;5(2):22-28.
4. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
5. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. (2022). An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci;11(10):84.
6. Sbodio JI, Snyder SH, Paul BD. (2019). Redox mechanisms in neurodegeneration: from disease outcomes to therapeutic opportunities. Antioxidants & Redox Signaling. ;30(11):1450-1499.
7. Kovacic P, Somanathan R. (2012). Redox processes in neurodegenerative disease involving reactive oxygen species. Current neuropharmacology;10(4):289-302.
8. La Rosa P, Petrillo S, Bertini ES, Piemonte F. (2020). Oxidative stress in DNA repeat expansion disorders: a focus on NRF2 signaling involvement. Biomolecules;10(5):702.
9. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. (2023). Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences;6(4):12-17.
10. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. (2023). Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences;10((9): 72-75
11. Obeagu EI. (2018). An update on micro-RNA in sickle cell disease. Int J Adv Res Biol Sci; 5:157-158.
12. Obeagu EI, Babar Q. (2021). Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research;3(5):2768-2487.
13. Obeagu EI. (2023). Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci;10(10):41-42.
14. Renoux C, Joly P, Faes C, Mury P, Eglenen B, et all., (2018). Association between oxidative stress, genetic factors, and clinical severity in children with sickle cell anemia. The Journal of pediatrics; 195:228-235.
15. Gueye Tall F, Martin C, Ndour EH, Faes C, Deme Ly I, et all., (2020). Influence of oxidative stress biomarkers and genetic polymorphisms on the clinical severity of hydroxyurea-free senegalese children with sickle cell anemia. Antioxidants;9(9):863.
16. Juan CA, Pérez de la Lastra JM, Plou FJ, Pérez-Lebeña E. (2021). The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. International journal of molecular sciences;22(9):4642.
17. Obeagu EI, Obeagu GU. (2023). Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research;6(1):2768-0487.
18. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. (2023). Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci;10(3):81-89.
19. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. (2018). Expression of micro-RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci;4(3):26-32.
20. Obeagu EI. (2018). Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci;5(11):13-15.
21. Obeagu EI, Obeagu GU. (2023). Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. Jun 10;6(2):10-13.
22. Silva M, Faustino P. (2023). From stress to sick (le) and back again–oxidative/antioxidant mechanisms, genetic modulation, and cerebrovascular disease in children with sickle cell anemia. Antioxidants;12(11):1977.
23. Deng M, Sun J, Peng L, Huang Y, Jiang W, et all., (2022). Scutellarin acts on the AR-NOX axis to remediate oxidative

stress injury in a mouse model of cerebral ischemia/reperfusion injury. Phytomedicine; 103:154214.
24. Obeagu EI, Mohamod AH. (2023). An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci;10(4):45-48.
25. Edward U, Osuorji VC, Nnodim J, Obeagu EI. (2022). Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. Mar 4;2(1):218-234.
26. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
27. Obeagu EI. (2018). Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci;4(11):33-35.
28. Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. (2017). Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxidative medicine and cellular longevity;(1):2525967.
29. Ifeanyi OE, Stella EI, Favour AA. (2018). Antioxidants In the Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) (cited 2021 Mar 4); 3.
30. Buhari HA, Ahmad AS, Obeagu EI. (2023). Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 4(1).
31. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, ET ALL., (2015). Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research;8(3):261-265.
32. Obeagu EI. (2023). BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences;3(1):1-6.
33. Obeagu EI, Obeagu GU. (2024). Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology;2(3):58-66.
34. Gueye Tall F, Martin C, Ndour EH, Faes C, Deme Ly I, ET ALL., (2020). Influence of oxidative stress biomarkers and genetic polymorphisms on the clinical severity of hydroxyurea-free senegalese children with sickle cell anemia. Antioxidants;9(9):863.
35. Silva DG, Junior EB, de Souza Torres L, Júnior OR, et all., (2011). Bonini-Domingos CR, De Almeida EA. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia. Blood Cells, Molecules, and Diseases;47(1):23-28.
36. Consoli V, Sorrenti V, Grosso S, Vanella L. (2021). Heme oxygenase-1 signaling and redox homeostasis in physiopathological conditions. Biomolecules;11(4):589.
37. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, et all., (2015). Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences;2(1):502-507.
38. Obeagu EI, Obeagu GU. (2023). Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences; 6 (2): 10-13.
39. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. (2014). Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences;3(3):1000-1005.
40. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. (2014). Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci;3(3):1000-1005.
41. Obeagu EI, Opoku D, Obeagu GU. (2023). Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci;10(2):160-163.
42. Ifeanyi E. (2015). Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH; 4(6): 258-259
43. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. (2014). Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci;3(3):1000-1005.
44. Ifeanyi OE, Stanley MC, Nwakaego OB. (2014). Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci;3(3):1046-1050.
45. Ifeanyi EO, Uzoma GO. (2020). Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res; 2:1-4.
46. Obeagu EI, Obeagu GU. (2024). Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology; 2 (3).:58-66.
47. Obeagu EI, Obeagu GU. (2024). Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science;2(2):7-15.
48. Obeagu EI, Obeagu GU. (2024). Implications of climatic change on sickle cell anemia: A review. Medicine. Feb 9;103(6): e37127.
49. Singh P, O'Toole TE, Conklin DJ, Hill BG, Haberzettl P. (2021). Endothelial progenitor cells as critical mediators of environmental air pollution-induced cardiovascular toxicity. *American Journal of Physiology-Heart and Circulatory Physiology*;320(4):H1440-1455.
50. Al-Naama LM, Hassan MA, Mehdi JK. (2015). Association of erythrocytes antioxidant enzymes and their cofactors with markers of oxidative stress in patients with sickle cell anemia. Qatar medical journal;2015(2):14.
51. Obeagu EI. Chromium VI: (2024). A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology; 2 (3).:81-95.
52. Obeagu EI. (2024). Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery:10-97.
53. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. (2024). Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine;103(2): e36898.
54. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. (2024). Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science;2(2):1-9.
55. Obeagu EI, Obeagu GU. (2024). Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine;2(1):47-56.
56. Wood KC, Hsu LL, Gladwin MT. (2008). Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free radical biology and medicine;44(8):1506-1528.
57. Tewari S, Brousse V, Piel FB, Menzel S, Rees DC. (2015). Environmental determinants of severity in sickle cell disease. Haematologica;100(9):1108.

DOI:10.31579/2639-4162/221